… 10 days in the molnupiravir group, p < 0.01. We recorded … treated with molnupiravir terminated
treatment due to ADRs. In conclusion, in a population of mostly vaccinated patients treated …

… treatment of COVID-19 in non-hospitalized adults at risk for progressing to severe disease.
These include ritonavir-boosted nirmatrelvir, remdesivir, and molnupiravir… of molnupiravir had …

… We found no significant difference in short term risk of severe, critical or fatal disease in
non-hospitalized individuals with COVID-19 at risk of disease progression treated with either …

… treatMent of covid-19 In the Community) trial in the United Kingdom did not reproduce such
benefits in nonhospitalized, vaccinated patients receiving molnupiravir … treatment for adults …

… (NMV-r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID…
US collaborative network to identify non-hospitalized high-risk adult patients with COVID-19 …

… molnupiravir regimen (800mg twice daily over 5 days) for treatment of non-hospitalised adults
… for randomised controlled trials (RCTs) of molnupiravir for COVID-19 and included only …

… To address this issue, clinical guidelines recommend that nonhospitalized adults with … In
this study describing the characteristics of US adults treated with molnupiravir in the outpatient …

… The use of molnupiravir to treat confirmed SARS-CoV-2 infection in vaccinated adults who
are at increased risk of an adverse outcomes when omicron was the dominant circulating …

… treatment with first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line
therapy (molnupiravir… of COVID-19 in nonhospitalized patients. N Engl J Med 2022;386:509–…

… common in patients treated with molnupiravir and nirmatrelvir/r. … Only non-hospitalized
patients with mild-to-moderate COVID-… the risk of any outcomes in adults at risk of severe disease …